Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax® challenge in vaccinia-naïve and vaccinia-immune individualsJanie Parrino, Barney S. Graham, Steven E. Rucker et al.|Vaccine|2006Cited by 95
Results from a first-in-human phase 1B study of a complement factor H inhibitor (GT103) in patients with non-small cell lung cancer (NSCLC).Jeffrey Clarke, Edward F. Patz, Tom Stinchcombe et al.|Journal of Clinical Oncology|2023Cited by 4